SCHEMBL1103064

SCHEMBL1103064

CC1(C)c2ccccc2N(c2c3ccccc3c(-c3ccccc3)c3ncccc23)c2ccccc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.33
HTT P42858 2/20 0.33
HSD17B10 Q99714 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
LMNA P02545 3/20 0.32
GAA P10253 1/20 0.32
KDM4E B2RXH2 3/20 0.31
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
MAPT P10636 2/20 0.31
MAPK1 P28482 1/20 0.31
HPGD P15428 2/20 0.31
HSP90AA1 P07900 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
NPC1 O15118 1/20 0.31
CKS1B P61024 1/20 0.31
GLO1 Q04760 1/20 0.31
SKP2 Q13309 1/20 0.31
AKT1 P31749 3/20 0.30
PDE4A P27815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102807 0.87 HSP90AA1 (0.36) HTTLMNAGAAKDM4EMEN1
SCHEMBL1103181 0.86 AKT1 (0.35) ALDH1A1HTTEGLN1LMNAGAA
SCHEMBL1103237 0.83 MAPT (0.39) ALDH1A1HTTHSD17B10GAAKDM4E
SCHEMBL1103072 0.82 HTT (0.33) ALDH1A1HTTHSD17B10LMNAGAA
SCHEMBL1103092 0.81 PAX8 (0.32) ALDH1A1HTTHSD17B10LMNAKDM4E
SCHEMBL1103075 0.81 MAPT (0.39) ALDH1A1HTTHSD17B10LMNAGAA
SCHEMBL12723365 0.80 KMT2A (0.33) HTTLMNAGAAKDM4EMEN1
SCHEMBL1102874 0.80 LMNA (0.33) ALDH1A1LMNAGAAMAPK1AKT1
SCHEMBL16314424 0.80 LMNA (0.32) ALDH1A1HTTHSD17B10LMNAKDM4E
SCHEMBL1103070 0.80 KMT2A (0.36) ALDH1A1HTTHSD17B10LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 ALDH1A1 1015/4885HTT 4390/4885HSD17B10 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.